Summary:
Colossal Biosciences raises $200 million in Series C funding.
Valuation reaches $10.2 billion, achieving decacorn status.
Focus on de-extinction of species like the dodo bird and woolly mammoth.
Funding will enhance genetic engineering technologies and expand conservation efforts.
Total funding raised since 2021 now stands at $435 million.
Colossal Biosciences, a groundbreaking de-extinction startup focused on resurrecting species like the dodo bird and the woolly mammoth, has successfully raised $200 million in a Series C funding round, valuing the company at an impressive $10.2 billion.
This latest investment comes from TWG Global, a holding company co-led by Mark Walter and Thomas Tull. Based in Dallas, Colossal Biosciences, which was launched in 2021, plans to utilize these funds to enhance its genetic engineering technologies and expand its software and hardware solutions related to de-extinction, conservation, and human health care.
The company believes that reviving extinct species will not only offer insights into evolutionary changes in current species but also aid in enhancing food production and minimizing environmental impact. Recently, Colossal has made strides in generating ancient genomes for the thylacine, an extinct carnivorous marsupial.
CEO and co-founder Ben Lamm expressed optimism, stating, “Our recent successes in creating the technologies necessary for our end-to-end de-extinction toolkit have been met with enthusiasm by the investor community. This funding will grow our team, support new technology development, expand our de-extinction species list, while continuing to allow us to carry forth our mission to make extinction a thing of the past.”
Just a year prior, Colossal raised $150 million in a Series B round to further its ambitious goals. In total, they have now secured $435 million since their inception.
Illustration: Dom Guzman
Comments